序号 |
标题 |
次数 |
作者 |
发布时间 |
80686 |
Edotreotide(DOTATOC),生长抑素类似物 |
157 |
h |
2024-12-11 |
80687 |
p-SCN-Bn-DOTA,127985-74-4,可用于标记多肽 |
147 |
h |
2024-12-11 |
80688 |
PAMAM-PEG-DOTA-Gd,聚酰胺-胺聚乙二醇DOTA钆 |
110 |
h |
2024-12-11 |
80689 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
145 |
h |
2024-12-11 |
80690 |
质粒构建的原理及方法 |
666 |
axc |
2024-12-11 |
80691 |
什么是基因过表达(gene overexpression) |
1328 |
axc |
2024-12-11 |
80692 |
m-PEG6-(CH2)6-phosphonic acid,cas:2028284-71-9 |
124 |
zcy |
2024-12-11 |
80693 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
103 |
h |
2024-12-11 |
80694 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
576 |
axc |
2024-12-11 |
80695 |
大环螯合物DOTA,DOTA-RGD |
97 |
h |
2024-12-11 |
80696 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
168 |
zcy |
2024-12-11 |
80697 |
基因敲除方法,基因敲除小鼠定制服务 |
206 |
axc |
2024-12-11 |
80698 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
130 |
zcy |
2024-12-11 |
80699 |
质粒构建的原理、步骤|质粒构建定制服务 |
495 |
axc |
2024-12-11 |
80700 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
149 |
h |
2024-12-11 |
80701 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
130 |
WYQ |
2024-12-11 |
80702 |
Stearic acid-PEG-CH2CO2H |
143 |
WYQ |
2024-12-11 |
80703 |
Dotatate,DOTA-奥曲肽 |
152 |
h |
2024-12-11 |
80704 |
螯合剂多肽DOTA-cyclo(RGDfK) |
123 |
h |
2024-12-11 |
80705 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
169 |
WYQ |
2024-12-11 |
80706 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
104 |
WYQ |
2024-12-11 |
80707 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
113 |
WYQ |
2024-12-11 |
80708 |
Hydroxy-PEG1-CH2-Boc |
122 |
kx |
2024-12-11 |
80709 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
162 |
WYQ |
2024-12-11 |
80710 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
119 |
h |
2024-12-11 |
80711 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
149 |
WYQ |
2024-12-11 |
80712 |
质粒构建的过程,制备方法 |
356 |
axc |
2024-12-11 |
80713 |
Tos-PEG1-CH2-Boc的应用和用途 |
166 |
kx |
2024-12-11 |
80714 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
86 |
h |
2024-12-11 |
80715 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
200 |
zcy |
2024-12-11 |
80716 |
Propargyl-PEG3-CH2CO2H |
152 |
WYQ |
2024-12-11 |
80717 |
DOTA多肽分子探针,619300-53-7 |
132 |
h |
2024-12-11 |
80718 |
t-Boc-Aminooxy-PEG2-CH2CO2tBu(CAS: 2100306-57-6) |
109 |
WYQ |
2024-12-11 |
80719 |
β-NF-CH2-OH |
145 |
kx |
2024-12-11 |
80720 |
PEG5-(CH2CO2t-Butyl)2(CAS: 211746-78-0) |
147 |
WYQ |
2024-12-11 |
80721 |
Hydroxy-PEG4-CH2-Boc |
168 |
kx |
2024-12-11 |
80722 |
PEG6-(CH2CO2t-Butyl)2(CAS: 211746-79-1) |
138 |
WYQ |
2024-12-11 |
80723 |
七肽DOTA-YLYEIAR,1262403-91-7 |
126 |
h |
2024-12-11 |
80724 |
质粒构建的原理与类型 |
191 |
axc |
2024-12-11 |
80725 |
Thalidomide-5-NH2-CH2-COOH |
151 |
kx |
2024-12-11 |
80726 |
Cbz-N-Amido-PEG4-CH2COOH(CAS: 1451362-51-8) |
153 |
WYQ |
2024-12-11 |
80727 |
HO-PEG10-CH2COOtBu |
101 |
|
2024-12-11 |
80728 |
t-butyl ester-PEG4-CH2COOH (CAS: 929087-83-2) |
159 |
WYQ |
2024-12-11 |
80729 |
什么是载体构建与质粒构建 |
242 |
axc |
2024-12-11 |
80730 |
Fmoc-Gly-NH-CH2-acetyloxy |
100 |
kx |
2024-12-11 |